Research Article
The Impact of Statins before High-Risk CABG on Postoperative Multiple Organ Function
Table 3
Independent risk factors for SOFA maximum greater than 11.
| | | Maximum SOFA score >11 | X2/t | value | Multivariate analysis OR (95% CI) | value | | YES (n = 251) | NO (n = 629) |
| | PST | 122 (48.6) | 381 (60.6) | 10.5 | 0.013 | 0.68 (0.50–0.92) | 0.013 | | ACE inhibitor or ARB | 56 (22.3) | 109 (17.3) | 2.9 | 0.104 | | | | Advanced age | 66.0 ± 7.7 | 64.8 ± 9.6 | 1.8 | 0.070 | | | | Female gender | 130 (51.8) | 225 (35.8) | 19.1 | <0.0001 | 1.93 (1.43–2.60) | <0.0001 | | Euroscore II | 9.5 ± 3.8 | 8.5 ± 3.8 | 3.5 | <0.0001 | 1.05 (1.01–1.09) | 0.012 | | BMI | 24.8 ± 3.2 | 25.0 ± 3.1 | 0.63 | 0.531 | | | | Hypertension | 149 (59.4) | 314 (49.9) | 6.4 | 0.014 | 1.40 (1.02–1.87) | 0.021 | | Current smoker | 61 (24.39) | 179 (28.5) | 1.6 | 0.241 | | | | Previous MI | 46 (18.3) | 65 (10.3) | 10.4 | 0.002 | 1.99 (1.30–3.04) | 0.002 | | Previous TIA or CVA | 9 (3.6) | 45 (7.2) | 3.9 | 0.061 | | | | Hypercholesterolaemia | 115 (45.8) | 247 (39.3) | 3.2 | 0.081 | | | | Previous AF | 39 (15.5) | 91 (10.3) | 0.16 | 0.675 | | | | Previous COPD | 17 (6.8) | 69 (11.0) | 3.6 | 0.060 | | | | Ventricular aneurysm | 20 (8.0) | 51 (8.1) | 0.35 | 0.601 | | | | Moderate and poor LVEF (<50%) | 152 (60.6) | 244 (38.8) | 33.5 | <0.0001 | 2.38 (1.76–3.21) | <0.0001 | | NYHA III and IV | 109 (43.4) | 206 (32.8) | 8.90 | 0.003 | 1.58 (1.17–2.13) | 0.003 | | Emergency CABG | 31 (12.4) | 16 (2.5) | 34.1 | <0.0001 | 5.64 (3.02–10.56) | <0.0001 | | Off pump | 147 (58.6) | 321 (51.0) | 4.1 | 0.044 | 1.36 (1.01–1.82) | 0.044 | | Duration of operation (hours) | 4.8 ± 1.5 | 4.2 ± 0.8 | 157.2 | <0.0001 | 1.68 (1.46–1.92) | <0.0001 |
|
|
PST: preoperative statin therapy; CABG: coronary artery bypass grafting; LVEF: left ventricular ejection fraction; BMI: body mass index; MI: myocardial infarction; TIA: prior transient ischemic attacks; CVA: cerebral vascular accident; PVD: previous peripheral vascular diseases; DM: diabetes mellitus; NYHA : New York Heart Association; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers.
|
